Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $68.00 price objective on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on HALO. Piper Sandler boosted their price target on Halozyme Therapeutics […]
More Stories
Venture Global (NYSE:VG) & Excelerate Energy (NYSE:EE) Financial Comparison
Excelerate Energy (NYSE:EE – Get Free Report) and Venture Global (NYSE:VG – Get Free Report) are both oils/energy companies, but...
Head to Head Analysis: Arbor Realty Trust (NYSE:ABR) & Apollo Commercial Real Estate Finance (NYSE:ARI)
Arbor Realty Trust (NYSE:ABR – Get Free Report) and Apollo Commercial Real Estate Finance (NYSE:ARI – Get Free Report) are...
Comparing TNF Pharmaceuticals (NASDAQ:TNFA) and Trinity Biotech (NASDAQ:TRIB)
Insider & Institutional Ownership 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares...
Head-To-Head Comparison: SMC Entertainment (OTCMKTS:SMCE) versus Marin Software (NASDAQ:MRIN)
Valuation and Earnings This table compares SMC Entertainment and Marin Software”s top-line revenue, earnings per share (EPS) and valuation. Gross...
Head-To-Head Survey: W. P. Carey (NYSE:WPC) versus Phillips Edison & Company, Inc. (NASDAQ:PECO)
W. P. Carey (NYSE:WPC – Get Free Report) and Phillips Edison & Company, Inc. (NASDAQ:PECO – Get Free Report) are...
Reviewing SolarBank (SUUN) & Its Competitors
SolarBank (NASDAQ:SUUN – Get Free Report) is one of 29 public companies in the “Electric & other services combined” industry,...